Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Northwest Biotherapeutics (NWBO) Operating Expenses: 2009-2025

Historic Operating Expenses for Northwest Biotherapeutics (NWBO) over the last 17 years, with Sep 2025 value amounting to $14.5 million.

  • Northwest Biotherapeutics' Operating Expenses fell 4.21% to $14.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $65.8 million, marking a year-over-year increase of 1.70%. This contributed to the annual value of $67.9 million for FY2024, which is 18.19% up from last year.
  • Per Northwest Biotherapeutics' latest filing, its Operating Expenses stood at $14.5 million for Q3 2025, which was down 2.62% from $14.9 million recorded in Q2 2025.
  • Northwest Biotherapeutics' Operating Expenses' 5-year high stood at $21.6 million during Q2 2022, with a 5-year trough of $10.4 million in Q3 2021.
  • For the 3-year period, Northwest Biotherapeutics' Operating Expenses averaged around $15.7 million, with its median value being $15.2 million (2024).
  • Data for Northwest Biotherapeutics' Operating Expenses shows a peak YoY increase of 135.74% (in 2021) and a maximum YoY decrease of 78.38% (in 2021) over the last 5 years.
  • Over the past 5 years, Northwest Biotherapeutics' Operating Expenses (Quarterly) stood at $10.7 million in 2021, then skyrocketed by 75.86% to $18.8 million in 2022, then dropped by 16.98% to $15.6 million in 2023, then rose by 20.16% to $18.7 million in 2024, then dropped by 4.21% to $14.5 million in 2025.
  • Its Operating Expenses stands at $14.5 million for Q3 2025, versus $14.9 million for Q2 2025 and $17.7 million for Q1 2025.